Relaxin to help people with cardio-metabolic disease
Relaxera’s goal is to develop synthetic human Relaxin-2 for the chronic treatment of the aging heart, Heart Failure with preserved Ejection Fraction (HFpEF), impaired glucose tolerance, and for organ protection in the field of transplant medicine.
NEWS AND EVENTS
Clinical Study “Relaxin for Heart Failure with preserved Ejection Fraction (HFpEF)”
Relaxera is designing a clinical phase II study demonstrating the beneficial and pleiotropic effects of relaxin in heart failure with preserved ejection fraction (HFpEF). Relaxera plan to commence this study within the next 3 years. The selection of patients for this upcoming study is the [...]
Relaxera and University of Pittsburgh announce research cooperation
As of December 2017, Relaxera and the group of Prof. Guy Salama (Heart and Vascular Institute of The University of Pittsburgh) entered into a research cooperation regarding the effects of relaxin in an animal model of HFpEF (“aged rat”). The focus of this research will, [...]
COOPERATIONS AND PROJECTS
HFpEF – Heart Failure with preserved Ejection Fraction
HFpEF represents a distinct sub-entity of heart failure. Like heart failure in general, HFpEF is characterized by the inability of the heart to provide, at normal filling pressures, an output adequate to meet the physiologically varying demands of the body (Paulus 2007, The Task Force 2008). …